Open Payments

Carle Foundation Hospital

Type
Teaching hospital
Where
Urbana, IL
Medicare CCN
140091
Received
$495,188 in 208 records, 2020 ($8,554 general, $486,633 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment11$8,554
2020Research payment197$486,633

By company

CompanyRecordsAmountYears
ABBVIE INC.46$133,3832020
Janssen Research & Development, LLC15$52,0732020
Regeneron Pharmaceuticals, Inc.21$50,4652020
Novartis Pharmaceuticals Corporation1$32,0352020
Medtronic Vascular, Inc.5$26,4252020
Amgen Inc.3$19,3412020
Celgene Corporation2$18,5222020
Ipsen Bioscience Inc.2$18,2932020
E.R. Squibb & Sons, L.L.C.2$17,3212020
Boston Scientific Corporation9$16,9492020
Takeda Pharmaceuticals U.S.A., Inc.10$16,5272020
Eisai Inc.6$13,6952020
PFIZER INC.17$13,3002020
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.1$10,0002020
Kowa Research Institute, Inc.4$8,0702020
SEAGEN INC.9$6,3122020
Incyte Corporation2$6,1672020
Premia Spine, Ltd.3$5,8402020
Daiichi Sankyo Inc.7$4,5522020
Genentech, Inc.2$4,0902020
Allergan, Inc.7$4,0482020
BIOTRONIK INC.13$3,4532020
Endologix LLC4$3,4382020
Roche Products Limited3$2,1952020
SANOFI US SERVICES INC.1$2,0002020
AstraZeneca Pharmaceuticals LP2$1,7502020
Stryker Corporation1$1,5002020
GE HEALTHCARE1$1,1542020
ConvaTec Inc.2$7772020
Merck Sharp & Dohme LLC4$6312020
Olympus America Inc.1$6052020
Oticon Medical, LLC1$1602020
Becton, Dickinson and Company1$1062020

By nature of payment

NatureRecordsAmount
Research payment197$486,633
Space rental or facility fees (teaching hospital only)5$5,750
Charitable Contribution3$1,932
Gift1$605
Education2$266

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Daiichi Sankyo Inc.$694Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-12-31Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-12-30ABBVIE INC.$1,204Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-12-30ABBVIE INC.$192Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-5332020
2020-12-22SEAGEN INC.$231Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-15Roche Products Limited$918Research paymentCash or cash equivalent DrugCROHN S DISEASE PROGRAM OLE2020
2020-12-11ABBVIE INC.$325Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-5332020
2020-12-11Merck Sharp & Dohme LLC$60Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2020
2020-12-11Merck Sharp & Dohme LLC$30Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2020
2020-12-09Regeneron Pharmaceuticals, Inc.$821Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-12-09Regeneron Pharmaceuticals, Inc.$821Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-12-09ABBVIE INC.$250Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-12-09ABBVIE INC.$250Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-5332020
2020-12-08Eisai Inc.$3,089Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-12-08Eisai Inc.$3,089Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-12-08Eisai Inc.$1,734Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-12-08Eisai Inc.$1,415Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-12-08Eisai Inc.$1,321Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-12-07ABBVIE INC.$1,540Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-5332020
2020-12-04Allergan, Inc.$1,000Research paymentCash or cash equivalentAURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o2020
2020-12-04Allergan, Inc.$1,000Research paymentCash or cash equivalentAURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o2020
2020-12-04Allergan, Inc.$1,000Research paymentCash or cash equivalentAURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o2020
2020-12-02PFIZER INC.$1,750Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-02PFIZER INC.$1,750Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-01Kowa Research Institute, Inc.$1,587Research paymentCash or cash equivalent DrugK-877-3022020
2020-12-01Takeda Pharmaceuticals U.S.A., Inc.$799Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTAN2020
2020-11-30ABBVIE INC.$1,204Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-11-27ABBVIE INC.$12,327Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-11-25ConvaTec Inc.$466Charitable ContributionCash or cash equivalentDuoDerm Device, WOUND THERAPEUTICS2020
2020-11-17AstraZeneca Pharmaceuticals LP$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentLYNPARZA Drug, Oncology2020
2020-11-16Boston Scientific Corporation$400Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-11Medtronic Vascular, Inc.$715Research paymentCash or cash equivalentArctic Front Device, AblationCryo AF Global Registry2020
2020-11-05ABBVIE INC.$286Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-11-05ABBVIE INC.$250Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-11-03Kowa Research Institute, Inc.$2,131Research paymentCash or cash equivalent DrugK-877-3022020
2020-11-02Boston Scientific Corporation$1,701Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTSMART MSP2020
2020-11-02Merck Sharp & Dohme LLC$41Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2020
2020-10-27Janssen Research & Development, LLC$4,690Research paymentCash or cash equivalentA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-10-26Takeda Pharmaceuticals U.S.A., Inc.$48Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-10-26Takeda Pharmaceuticals U.S.A., Inc.$18Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-10-26Takeda Pharmaceuticals U.S.A., Inc.$8Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-10-23SEAGEN INC.$231Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-10-21Regeneron Pharmaceuticals, Inc.$9,716Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-10-21ABBVIE INC.$483Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-10-17Merck Sharp & Dohme LLC$500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2020
2020-10-14Regeneron Pharmaceuticals, Inc.$1,798Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-10-08Regeneron Pharmaceuticals, Inc.$8,000Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-10-08Regeneron Pharmaceuticals, Inc.$3,415Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-10-02Takeda Pharmaceuticals U.S.A., Inc.$2,500Research paymentCash or cash equivalentAN OPEN-LABEL, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB IV, ADAL2020
2020-10-01Genentech, Inc.$2,045Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2020
2020-09-30ABBVIE INC.$4,017Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-09-29Eisai Inc.$3,047Research paymentCash or cash equivalentFycompa Drug, NeurologyA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad2020
2020-09-24Kowa Research Institute, Inc.$756Research paymentCash or cash equivalent DrugK-877-3022020
2020-09-21Boston Scientific Corporation$375Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTSMART MSP2020
2020-09-17Ipsen Bioscience Inc.$9,543Research paymentCash or cash equivalentAn Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracilLeu2020
2020-09-16Regeneron Pharmaceuticals, Inc.$132Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-09-09ABBVIE INC.$3,845Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-5332020
2020-09-08ABBVIE INC.$250Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-09-03Kowa Research Institute, Inc.$3,595Research paymentCash or cash equivalent DrugK-877-3022020
2020-09-01ABBVIE INC.$7,196Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-08-26Regeneron Pharmaceuticals, Inc.$94Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-08-25Medtronic Vascular, Inc.$2,546Research paymentCash or cash equivalentArctic Front Device, AblationCryo AF Global Registry2020
2020-08-21Amgen Inc.$925Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-08-05Regeneron Pharmaceuticals, Inc.$3,178Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-08-05Oticon Medical, LLC$160Education (8 payments)Cash or cash equivalentPONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device2020
2020-07-30ABBVIE INC.$4,793Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-07-29ABBVIE INC.$4,600Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYM14-3472020
2020-07-27SEAGEN INC.$231Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-07-27SEAGEN INC.$231Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-07-21BIOTRONIK INC.$1,000Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-07-20Janssen Research & Development, LLC$8,578Research paymentCash or cash equivalentA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-07-17Olympus America Inc.$605GiftIn-kind items and servicesUltrasonic Generators Device, Urology/Gynecology2020
2020-07-16Endologix LLC$2,457Research paymentCash or cash equivalentALTO Device, Cardiology/Vascular DiseasesELEVATE IDE2020
2020-07-16Endologix LLC$756Research paymentCash or cash equivalentALTO Device, Cardiology/Vascular DiseasesELEVATE IDE2020
2020-07-16Roche Products Limited$336Research paymentCash or cash equivalent DrugCROHN S DISEASE PROGRAM OLE2020
2020-07-16Endologix LLC$150Research paymentCash or cash equivalentALTO Device, Cardiology/Vascular DiseasesELEVATE IDE2020
2020-07-16Endologix LLC$75Research paymentCash or cash equivalentALTO Device, Cardiology/Vascular DiseasesELEVATE IDE2020
2020-07-09ABBVIE INC.$536Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-07-08Stryker Corporation$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentUNIVERSAL MANDIBLE Device, CRANIOMAXILLOFACIAL2020
2020-07-06ABBVIE INC.$10,845Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-07-06Boston Scientific Corporation$2,876Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTSMART MSP2020
2020-06-30ABBVIE INC.$16,692Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-06-28PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-06-28PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-06-26ABBVIE INC.$50Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-06-17Regeneron Pharmaceuticals, Inc.$2,401Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-06-17Regeneron Pharmaceuticals, Inc.$136Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-06-17Allergan, Inc.$50Research paymentCash or cash equivalentA SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION2020
2020-06-17Allergan, Inc.$49Research paymentCash or cash equivalentA SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION2020
2020-06-16MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.$10,000Research paymentCash or cash equivalentA STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY , PHARMACOKINETICS OF SINGLE ASCENDING DOSE OF MT-3921 IN SUBJECTS WITH 2020
2020-06-12Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-06-11SEAGEN INC.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentPADCEV Biological, Oncology2020
2020-06-09BIOTRONIK INC.$212Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$207Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-09BIOTRONIK INC.$166Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-06-04Premia Spine, Ltd.$1,801Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2020
2020-05-29ABBVIE INC.$5,810Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-05-28PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-05-28PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-05-26ABBVIE INC.$463Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-05-21Ipsen Bioscience Inc.$8,750Research paymentCash or cash equivalentONIVYDE Drug, OncologyAn Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracilLeu2020
2020-05-20Regeneron Pharmaceuticals, Inc.$1,023Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-05-20Regeneron Pharmaceuticals, Inc.$42Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-05-19Amgen Inc.$750Research paymentCash or cash equivalentPh 2b UC Study2020
2020-05-19Takeda Pharmaceuticals U.S.A., Inc.$109Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-05-19Takeda Pharmaceuticals U.S.A., Inc.$11Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-05-07Medtronic Vascular, Inc.$2,994Research paymentCash or cash equivalentArctic Front Device, AblationCryo AF Global Registry2020
2020-05-07ABBVIE INC.$1,593Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-05-01PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-04-27Regeneron Pharmaceuticals, Inc.$3,000Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-04-27Regeneron Pharmaceuticals, Inc.$742Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-04-27Regeneron Pharmaceuticals, Inc.$478Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-04-27Regeneron Pharmaceuticals, Inc.$136Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-04-24Medtronic Vascular, Inc.$3,875Research paymentCash or cash equivalentArctic Front Device, AblationCryo AF Global Registry2020
2020-04-23ABBVIE INC.$3,187Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-04-23Janssen Research & Development, LLC$1,876Research paymentCash or cash equivalentA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-04-23ABBVIE INC.$1,593Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-04-21Boston Scientific Corporation$8,274Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2020
2020-04-17ConvaTec Inc.$311Charitable ContributionCash or cash equivalentDuoDerm Device, WOUND THERAPEUTICS2020
2020-04-14Regeneron Pharmaceuticals, Inc.$2,989Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-04-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-04-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-04-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-04-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-04-13ABBVIE INC.$50Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-04-06Boston Scientific Corporation$1,877Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTSMART MSP2020
2020-03-31ABBVIE INC.$1,878Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-03-25ABBVIE INC.$6,330Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-03-18Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-03-18Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-03-18Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-03-18Daiichi Sankyo Inc.$642Research paymentCash or cash equivalentSavaysa Drug, ThrombosisENVISAGE2020
2020-03-12Janssen Research & Development, LLC$8,036Research paymentCash or cash equivalentA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-03-11AstraZeneca Pharmaceuticals LP$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLOKELMA Drug, Cardiovascular and Metabolism2020
2020-03-11SEAGEN INC.$270Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-03-11SEAGEN INC.$163Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-03-06SEAGEN INC.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPADCEV Biological, Oncology2020
2020-03-05Regeneron Pharmaceuticals, Inc.$5,359Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-03-05ABBVIE INC.$28Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-03-04Premia Spine, Ltd.$1,518Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2020
2020-03-03ABBVIE INC.$50Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-03-02ABBVIE INC.$13,658Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-02-26Incyte Corporation$700Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-02-25ABBVIE INC.$583Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-02-25Becton, Dickinson and Company$106EducationIn-kind items and services2020
2020-02-24ABBVIE INC.$1,027Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-02-20Regeneron Pharmaceuticals, Inc.$3,135Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-02-20ABBVIE INC.$81Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-02-19SEAGEN INC.$2,455Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-02-18SANOFI US SERVICES INC.$2,000Research paymentCash or cash equivalentAn Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa2020
2020-02-18Boston Scientific Corporation$680Research paymentCash or cash equivalentGENERAL - TACHY Device, TACHYLSS OF 4 SITE2020
2020-02-18Boston Scientific Corporation$500Research paymentCash or cash equivalentGENERAL - TACHY Device, TACHYLSS OF 4 SITE2020
2020-02-18Boston Scientific Corporation$264Research paymentCash or cash equivalentGENERAL - TACHY Device, TACHYLSS OF 4 SITE2020
2020-02-13Allergan, Inc.$748Research paymentCash or cash equivalentA SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION2020
2020-02-13ABBVIE INC.$100Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-02-10Medtronic Vascular, Inc.$16,295Research paymentCash or cash equivalentArctic Front Device, AblationCryo AF Global Registry2020
2020-02-04Premia Spine, Ltd.$2,520Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2020
2020-02-04Takeda Pharmaceuticals U.S.A., Inc.$570Research paymentCash or cash equivalentA PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH 2020
2020-02-04Takeda Pharmaceuticals U.S.A., Inc.$500Research paymentCash or cash equivalentA PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH 2020
2020-01-31ABBVIE INC.$13,650Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-01-31ABBVIE INC.$1,297Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-01-31GE HEALTHCARE$1,154Charitable ContributionCash or cash equivalent2020
2020-01-31ABBVIE INC.$702Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-6752020
2020-01-29Amgen Inc.$17,666Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-01-29ABBVIE INC.$55Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-01-27Novartis Pharmaceuticals Corporation$32,035Research paymentCash or cash equivalentBEOVU Drug, OPHTHALMOLOGYA TWO YEAR, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VE2020
2020-01-27E.R. Squibb & Sons, L.L.C.$11,355Research paymentCash or cash equivalentEMPLICITI Biological, OncologyProspective REsearch Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE)2020
2020-01-23Genentech, Inc.$2,045Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2020
2020-01-23ABBVIE INC.$1,593Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020
2020-01-22Celgene Corporation$8,336Research paymentCash or cash equivalentPhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14)2020
2020-01-22Incyte Corporation$5,467Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-01-22ABBVIE INC.$3,132Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2822020
2020-01-21Janssen Research & Development, LLC$28,493Research paymentCash or cash equivalentA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Regeneron Pharmaceuticals, Inc.$3,042Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS2020
2020-01-21Janssen Research & Development, LLC$53Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$39Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$24Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$12Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$7Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$7Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$2Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$1Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-21Janssen Research & Development, LLC$1Research paymentIn-kind items and servicesA Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease2020
2020-01-16Takeda Pharmaceuticals U.S.A., Inc.$11,961Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2020
2020-01-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-01-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-01-13ABBVIE INC.$1,794Research paymentCash or cash equivalentRINVOQ Drug, IMMUNOLOGYM14-2342020

The latest 200 records of 208.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Champaign CountyUrbana city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.

MeasurePlace (city or town)
Urbana, IL
County
Champaign County, IL
State
Illinois
Population B0100339,341208,74112,694,798
Population, 2020 census P138,336205,86512,812,508
Median age B0100226.130.739.0
Under 18 B0100113.2%19.1%21.8%
65 and over B0100111.5%13.9%17.0%
Households B1100116,85685,4725,036,449
Foreign born B0500221.2%14.2%14.7%
Median household income B19013$45,346$63,683$83,390
Median family income B19113$86,209$100,396$106,018
Per capita income B19301$32,592$38,439$46,406
Poverty rate B1700128.0%19.1%11.8%
Unemployment rate B230254.7%4.3%5.8%
Civilian labor force B2302520,316104,8766,652,134
Mean commute (minutes) B0801314.216.927.8
Bachelor's degree or higher B1500356.7%46.2%37.8%
Housing units B2500119,22895,1155,457,452
Owner-occupied B2500337.3%54.0%67.1%
Renters B2500362.7%46.0%32.9%
Median home value B25077$184,900$211,500$263,300
Median gross rent B25064$972$1,051$1,274
White, not Hispanic B0300252.9%62.4%58.1%
Black B0300218.7%13.4%13.3%
Hispanic or Latino B0300210.1%8.3%18.8%
Asian B0300214.2%11.4%5.9%
American Indian and Alaska Native B030020.0%0.1%0.1%

Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); Unemployment rate: 5.7% in Sep 2016 to 4.6% in Sep 2026; low 3.6%, high 18.3% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.